eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
 
2/2020
vol. 36
 
Share:
Share:
more
 
 
abstract:
Review paper

Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?

Robert Dziura
1
,
Paweł Macek
2, 3
,
Jolanta Smok-Kalwat
1
,
Stanisław Góźdź
1, 2

1.
Department of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland
2.
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
3.
Department of Epidemiology and Cancer Control, Holy Cross Cancer Centre, Kielce, Poland
Medical Studies/Studia Medyczne 2020; 36 (2): 142–147
Online publish date: 2020/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The incidence of pancreatic cancer has been increasing in recent years. It is expected to be the second or the third leading cause of cancer deaths in high-income countries in the next decade. Standard therapeutic management for patients with resectable pancreatic cancer is surgical resection followed by adjuvant chemotherapy. The main reason for neoadjuvant therapy is that the prognosis with current strategies is unsatisfactory, and we need new treatments to improve overall survival as well as the quality of life of the patients suffering from pancreatic cancer. The aim of this paper is to provide an overview of the recent data on the subject of neoadjuvant treatment concerning resectable and borderline resectable group of patients.
keywords:

pancreatic cancer, neoadjuvant treatment, chemotherapy

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe